Q1 2025 DiaMedica Therapeutics Inc Earnings Call Transcript
Key Points
- DiaMedica Therapeutics Inc (DMAC) is making substantial progress in its clinical development programs, particularly in the preeclampsia and stroke areas.
- The company is close to identifying a target dose for its phase 2 preeclampsia trial, with preliminary top-line results expected between June and July.
- Enrollment in the stroke program is progressing steadily, with participant enrollment reaching between the 20th and 25th percentile mark.
- The company has engaged an experienced stroke neurologist to support site engagement and maintain enrollment momentum in the Remedy II trial.
- DiaMedica Therapeutics Inc (DMAC) has a strong financial position with a total combined cash and investments of $37.3 million as of March 31, 2025, providing a runway into Q3 of 2026.
- The company's net cash used in operating activities increased to $7.1 million for the first quarter of 2025, up from $6.7 million in the same period of 2024.
- Research and development expenses rose significantly to $5.7 million for the three months ended March 31, 2025, compared to $3.7 million for the same period in 2024.
- General and administrative expenses increased to $2.5 million for the three months ended March 31, 2025, from $2.1 million in the same period of 2024.
- The company anticipates that R&D expenses will moderately increase in future periods due to the continuation of the Remedy II trial and expansion of the DM 199 clinical development program.
- Interest income decreased, resulting in a net other income of $443,000 for the three months ended March 31, 2025, compared to $597,000 for the same period in 2024.
Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics first quarter 2025 conference call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.Diamedica.com in the investor relations section. Before DiaMedica proceeds with its remarks, please note that the company will be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements.
More information, including factors that could cause actual results to differ from projected results, appears in the section entitled Cautionary Note regarding forward-looking statements. In the company's press release issued yesterday and under the heading Risk factors in the company's most recent annual report on Form 10K and most recent quarterly report, Form 10Q. DiaMedica's SEC filings are available on the SEC's website www
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
